(ABCL) Abcellera Biologics - Ratings and Ratios
Antibody, Discovery, Therapeutics, Platform, Development
ABCL EPS (Earnings per Share)
ABCL Revenue
Description: ABCL Abcellera Biologics August 26, 2025
Abcellera Biologics Inc (NASDAQ:ABCL) is a Canadian biotechnology company. The firms quarterly tax provision is a critical aspect of its financial reporting, reflecting the complexities of its financial and operational activities.
From a financial perspective, ABCLs market capitalization stands at approximately $1.28 billion USD, indicating a significant presence in the biotechnology sector. The companys forward Price-to-Earnings (P/E) ratio is 27.47, suggesting that investors are pricing in future growth expectations. However, the Return on Equity (RoE) is -15.91%, indicating that the company is currently operating at a loss.
Key economic drivers for ABCL include the development and commercialization of its biotechnology products, research and development (R&D) expenditures, and the overall demand for its offerings in the healthcare industry. The companys ability to manage its R&D expenses, navigate regulatory environments, and bring innovative products to market will be crucial in driving future growth.
In terms of KPIs, investors should closely monitor ABCLs revenue growth, R&D pipeline progress, and cash burn rate. The companys ability to maintain a stable cash position while advancing its product pipeline will be essential in determining its long-term success. Additionally, the biotechnology sectors overall trends, including advancements in technology and shifts in regulatory policies, will also impact ABCLs performance.
To evaluate ABCLs stock performance, one should consider its volatility, as indicated by its Average True Range (ATR) and Beta. With an ATR of 0.28, representing a 6.49% daily price movement, and a Beta of 0.649, ABCLs stock exhibits relatively moderate volatility compared to the broader market.
ABCL Stock Overview
| Market Cap in USD | 1,659m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-12-11 |
ABCL Stock Ratings
| Growth Rating | -21.6% |
| Fundamental | 21.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 26.1% |
| Analyst Rating | 4.56 of 5 |
ABCL Dividends
Currently no dividends paidABCL Growth Ratios
| Growth Correlation 3m | 64.4% |
| Growth Correlation 12m | 64.3% |
| Growth Correlation 5y | -91.5% |
| CAGR 5y | -34.22% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.39 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.52 |
| Sharpe Ratio 12m | -0.95 |
| Alpha | 30.19 |
| Beta | 0.690 |
| Volatility | 77.96% |
| Current Volume | 13523.8k |
| Average Volume 20d | 4532.3k |
| Stop Loss | 3.6 (-7.9%) |
| Signal | -0.36 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-165.7m TTM) > 0 and > 6% of Revenue (6% = 1.97m TTM) |
| FCFTA -0.10 (>2.0%) and ΔFCFTA 2.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2054 % (prev 2121 %; Δ -67.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.06 (>3.0%) and CFO -80.8m > Net Income -165.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.07 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (298.5m) change vs 12m ago 1.46% (target <= -2.0% for YES) |
| Gross Margin -209.5% (prev -85.51%; Δ -124.0pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 2.34% (prev 2.34%; Δ -0.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -28.40 (EBITDA TTM -164.0m / Interest Expense TTM 8.05m) >= 6 (WARN >= 3) |
Altman Z'' 4.35
| (A) 0.48 = (Total Current Assets 742.1m - Total Current Liabilities 67.0m) / Total Assets 1.40b |
| (B) 0.03 = Retained Earnings (Balance) 36.6m / Total Assets 1.40b |
| (C) -0.16 = EBIT TTM -228.6m / Avg Total Assets 1.41b |
| (D) 2.09 = Book Value of Equity 825.6m / Total Liabilities 395.0m |
| Total Rating: 4.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 21.56
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -11.14% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda -0.30 = -2.50 |
| 6. ROIC - WACC (= -29.30)% = -12.50 |
| 7. RoE -15.91% = -2.50 |
| 8. Rev. Trend -62.92% = -4.72 |
| 9. EPS Trend 25.71% = 1.29 |
What is the price of ABCL shares?
Over the past week, the price has changed by -29.55%, over one month by -32.24%, over three months by -7.78% and over the past year by +43.75%.
Is Abcellera Biologics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABCL is around 2.85 USD . This means that ABCL is currently overvalued and has a potential downside of -27.11%.
Is ABCL a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABCL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.3 | 138.6% |
| Analysts Target Price | 9.3 | 138.6% |
| ValueRay Target Price | 3.2 | -18.9% |
ABCL Fundamental Data Overview November 04, 2025
P/E Forward = 27.4725
P/S = 50.4478
P/B = 1.7745
Beta = 0.69
Revenue TTM = 32.9m USD
EBIT TTM = -228.6m USD
EBITDA TTM = -164.0m USD
Long Term Debt = 142.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.79m USD (from shortTermDebt, last quarter)
Debt = 142.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.25b USD (1.66b + Debt 142.1m - CCE 553.1m)
Interest Coverage Ratio = -28.40 (Ebit TTM -228.6m / Interest Expense TTM 8.05m)
FCF Yield = -11.14% (FCF TTM -139.0m / Enterprise Value 1.25b)
FCF Margin = -422.8% (FCF TTM -139.0m / Revenue TTM 32.9m)
Net Margin = -503.9% (Net Income TTM -165.7m / Revenue TTM 32.9m)
Gross Margin = -209.5% ((Revenue TTM 32.9m - Cost of Revenue TTM 101.8m) / Revenue TTM)
Gross Margin QoQ = 58.68% (prev -903.4%)
Tobins Q-Ratio = 0.89 (Enterprise Value 1.25b / Total Assets 1.40b)
Interest Expense / Debt = 5.67% (Interest Expense 8.05m / Debt 142.1m)
Taxrate = 4.45% (-1.62m / -36.3m)
NOPAT = -218.5m (EBIT -228.6m * (1 - 4.45%)) [loss with tax shield]
Current Ratio = 11.07 (Total Current Assets 742.1m / Total Current Liabilities 67.0m)
Debt / Equity = 0.14 (Debt 142.1m / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = -0.30 (negative EBITDA) (Net Debt 49.6m / EBITDA -164.0m)
Debt / FCF = -0.36 (negative FCF - burning cash) (Net Debt 49.6m / FCF TTM -139.0m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = -11.82% (Net Income -165.7m / Total Assets 1.40b)
RoE = -15.91% (Net Income TTM -165.7m / Total Stockholder Equity 1.04b)
RoCE = -19.32% (EBIT -228.6m / Capital Employed (Equity 1.04b + L.T.Debt 142.1m))
RoIC = -20.98% (negative operating profit) (NOPAT -218.5m / Invested Capital 1.04b)
WACC = 8.31% (E(1.66b)/V(1.80b) * Re(8.56%) + D(142.1m)/V(1.80b) * Rd(5.67%) * (1-Tc(0.04)))
Discount Rate = 8.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.45%
Fair Price DCF = unknown (Cash Flow -139.0m)
EPS Correlation: 25.71 | EPS CAGR: 33.47% | SUE: 4.0 | # QB: 1
Revenue Correlation: -62.92 | Revenue CAGR: -47.67% | SUE: 4.0 | # QB: 1
Additional Sources for ABCL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle